Calcium/Calmodulin Mediates Cardiomyocyte Ferroptosis in Myocardial Infarction Through Iron Overload / 中国生物化学与分子生物学报

Myocardial infarction(MI), an acute coronary syndrome that poses a serious risk to human health, involves multiple pathophysiological processes, including calcium overload. Existing therapeutic approaches and preventive measures have limitations and cannot effectively repair myocardial cells with poor regenerative potential. Exploring multiple programmed modes of cardiomyocyte death could help find potential targets for the treatment of myocardial infarction, and the potential role of ferroptosis as a novel mode of cell death in myocardial infarction has attracted great attention. The aim of this study was to investigate whether Ca

The relationship between serum fibrinogen-like protein 2 concentrations and 30-day mortality of patients with traumatic brain injury.

BACKGROUND: Fibrinogen-like protein 2 (FGL2) is an inflammatory procoagulant protein. We discerned the impact of serum FGL2 on trauma severity and 30-day mortality in patients with traumatic brain injury (TBI). METHODS: A total of 114 severe TBI patients were subjected to assessment of trauma severity using the Glasgow coma scale (GCS). Measurement of the serum concentrations of FGL2 was done. 114 matched control subjects for their age and sex were included for comparison of serum concentration of FGL2. RESULTS: The concentration of FGL2 was dramatically increased in the patients as compared with the control subjects. FGL2 concentration was inversely correlated with GCS score among the patients. The non-survivors within 30 days exhibited substantially higher FGL2 concentrations than the alive. FGL2 concentrations discriminated the patients at risk of 30-day death with significantly high area under receiver operating characteristic curve. Serum FGL2 emerged as an independent predictor for mortality and overall survival at 30 days after head trauma. CONCLUSIONS: Serum FGL2 is a promising biomarker for assessing the severity and prognosis in severe TBI.

Serum CXCL12 concentration in patients with severe traumatic brain injury are associated with mortality.

BACKGROUND: CXC chemokine ligand-12 (CXCL12) is released during brain injury. The objective of this study was to investigate relationship between serum CXCL12 concentration, mortality and trauma severity in patients with traumatic brain injury (TBI). METHODS: We determined serum CXCL12 concentration of 132 controls and 132 patients with severe TBI. Trauma severity was assessed using Glasgow Coma Scale (GCS) score. The end-point of the study was 30-day mortality. RESULTS: Serum CXCL12 concentration were significantly higher in the patients than in the controls (13.3±6.8 vs. 1.5±0.5 ng/ml, P<0.001). There was a negative correlation between CXCL12 concentration and GCS scores (r=-0.588, P<0.001). The optimal cutoff value of CXCL12 as a mortality indicator was estimated to be 15.4 ng/ml, which yielded a sensitivity of 71.0% and a specificity of 72.2%, with the area under curve at 0.808 [95% confidence (CI), 0.730-0.871]. Serum CXCL12 concentration>19.5 ng/ml were associated independently with 30-day mortality (odds ratio, 6.951; 95% CI, 2.027-18.477; P<0.001) and 30-day overall survival (hazard ratio, 4.398; 95% CI, 2.088-15.286; P<0.001). CONCLUSIONS: Increased serum CXCL12 concentration is associated highly with trauma severity and mortality following TBI.

Plasma levels of adrenomedullin in patients with traumatic brain injury: potential contribution to prognosis.

High plasma levels of adrenomedullin have been associated with stroke severity and clinical outcomes. This study aimed to analyze plasma levels of adrenomedullin in traumatic brain injury and their association with prognosis. One hundred and forty-eight acute severe traumatic brain injury and 148 sex- and age-matched healthy controls were recruited in this study. Plasma adrenomedullin concentration was measured by enzyme-linked immunosorbent assay. Unfavorable outcome was defined as Glasgow Outcome Scale score of 1-3. Compared to controls, the patients had significantly higher plasma concentrations of adrenomedullin, which were also highly associated negatively with Glasgow Coma Scale score. Plasma adrenomedullin level was proved to be an independent predictor for 6-month mortality and unfavorable outcome of patients in a multivariate analysis. A receiver operating characteristic curve was configured to show that a baseline plasma adrenomedullin level predicted 6-month mortality and unfavorable outcome of patients with high area under curve. The predictive performance of the plasma adrenomedullin concentration was also similar to that of Glasgow Coma Scale score for the prediction of 6-month mortality and unfavorable outcome of patients. In a combined logistic-regression model, adrenomedullin improved the area under curve of Glasgow Coma Scale score for the prediction of 6-month mortality and unfavorable outcome of patients, but the differences did not appear to be statistically significant. Thus, high plasma levels of adrenomedullin are associated with head trauma severity, and may independently predict long-term clinical outcomes of traumatic brain injury.